诺和诺德向FDA递交CagriSema上市申请诺和诺德今日宣布,已向美国FDA递交CagriSema的新药申请(NDA)。该疗法拟与减少热量饮食及增加体力活动联合,用于伴有至少一种与体重相关共病的肥胖或超重成人患者,以降低体重并长期维持减重效果。CagriSema是一款由长效胰淀素类似物cagrilintide(2.4 mg)和semaglutide(2.4 mg)组成的固定剂量联合疗法,设计为...
Source Link诺和诺德向FDA递交CagriSema上市申请诺和诺德今日宣布,已向美国FDA递交CagriSema的新药申请(NDA)。该疗法拟与减少热量饮食及增加体力活动联合,用于伴有至少一种与体重相关共病的肥胖或超重成人患者,以降低体重并长期维持减重效果。CagriSema是一款由长效胰淀素类似物cagrilintide(2.4 mg)和semaglutide(2.4 mg)组成的固定剂量联合疗法,设计为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.